CN-122012714-A - Cervical cancer prognosis evaluation kit based on ITM2A mRNA expression level and application thereof

Abstract

The invention provides a cervical cancer prognosis evaluation kit based on an ITM2A mRNA expression level and application thereof, and belongs to the technical field of molecular detection. The kit comprises a primer pair capable of specifically amplifying human ITM2A gene sequences, and through detecting the expression levels of ITM2A genes and encoding proteins in cervical normal tissues and tumor tissues, the expression of ITM2A in the tumor tissues of cervical cancer patients is obviously down-regulated, and the kit for prognosis judgment of cervical cancer is developed based on the above findings, and has extremely important significance for risk assessment and prognosis prediction of cervical cancer patients.

Inventors

• WANG TAO
• LI HAINING
• WEI YUANJI
• YAO YI
• JI CHEN
• LI XIAOQIN
• YUAN HONGXIA

Assignees

• 甘肃省医学科学研究院

Dates

Publication Date

20260512

Application Date

20260226

Claims (9)

1. 1. A kit for prognosis evaluation of cervical cancer, characterized in that the kit comprises a detection reagent for specifically detecting the expression level of human ITM2A gene.
2. 2. The kit of claim 1, wherein the detection reagent comprises a primer pair capable of specifically amplifying the human ITM2A gene sequence.
3. 3. The kit according to claim 2, wherein the nucleotide sequences of the primer pairs are shown in SEQ ID NO.1 and SEQ ID NO. 2.
4. 4. The kit of claim 3, wherein the kit is a fluorescent quantitative PCR kit and the detection kit further comprises a fluorescent dye.
5. 5. The kit of claim 4, further comprising a reference gene detection reagent, wherein the reference gene is selected from GAPDH.
6. 6. The kit according to any one of claims 1 to 5, further comprising reagents for extracting total RNA of the sample, reverse transcription reagents and/or PCR reaction buffers.
7. 7. The kit of claim 6, wherein the sample is cervical tissue or paraffin embedded tissue of a cervical cancer patient.
8. 8. The primer pair for prognosis evaluation of cervical cancer is characterized in that the primer pair can specifically amplify the sequence of human ITM2A gene, and the sequence is shown as SEQ ID NO.1 and SEQ ID NO. 2.
9. 9. Use of a kit according to any one of claims 1 to 7 or a primer pair according to claim 8 for the preparation of a product for assessing prognosis of a cervical cancer patient.

Description

Cervical cancer prognosis evaluation kit based on ITM2A mRNA expression level and application thereof Technical Field The invention relates to the technical field of molecular detection, in particular to a cervical cancer prognosis evaluation kit based on an ITM2A mRNA expression level and application thereof. Background Cervical cancer is one of the malignant tumors that severely threatens female health worldwide. Although the popularity of Human Papillomavirus (HPV) vaccination and cervical cancer screening has significantly reduced its morbidity and mortality, there is still a significant difference in the clinical prognosis for cervical cancer patients. Some patients have a good prognosis after receiving standard treatment and a high long-term survival rate, while others are prone to relapse, metastasis and even resistance to treatment, leading to poor clinical outcome. Therefore, the prognosis risk of cervical cancer patients is accurately estimated, and the method has important clinical significance for guiding individualized treatment decisions. Currently, prognosis evaluation of cervical cancer is mainly dependent on clinical pathological features such as tumor stage, lymph node metastasis state, etc. However, these indicators have limitations in predicting long-term survival and disease progression in patients, and do not fully meet the needs of personalized therapies. In recent years, with the development of molecular biology techniques, more and more research is beginning to focus on molecular changes in tumor microenvironments and their relationship to prognosis. However, existing biomarkers still have shortcomings in terms of specificity and sensitivity, and there is a need to discover new reliable molecular markers. Transmembrane protein 2A (Integral Membrane Protein a, ITM 2A) is a member of the BRICHOS domain protein family. Recent studies have shown that ITM2A is not a simple structural protein that plays an important role in a variety of biological processes, including cell differentiation, autophagy, and extracellular matrix interactions. However, with respect to the role of ITM2A in cervical cancer and its clinical significance, current research is still blank. To date, no study has clearly revealed the correlation of the mRNA expression level of ITM2A with clinical pathological features and survival prognosis of cervical cancer patients. Whether ITM2A can be used as a stable and reliable cervical cancer prognosis molecular marker, and whether the expression level of the ITM2A has predicted values for the progression-free survival (PFS) and the total survival (OS) of cervical cancer patients is not explored and solved. Based on the above, the field is urgent to find a molecular marker closely related to prognosis of cervical cancer, and develop a detection kit capable of objectively, accurately and conveniently evaluating prognosis risk of cervical cancer patients according to the molecular marker, so as to make up for the defect of the existing clinical pathological parameters in prognosis layering precision, and provide powerful molecular basis for clinicians to formulate more reasonable individualized treatment schemes. Disclosure of Invention In view of the above, the present invention provides a cervical cancer prognosis evaluation kit based on the expression level of ITM2A mRNA and application thereof, so as to solve the above problems. In order to achieve the above object, the present invention provides the following technical solutions: the invention provides a kit for prognosis evaluation of cervical cancer, which comprises a detection reagent for specifically detecting the expression level of human ITM2A genes. Preferably, the detection reagent comprises a primer pair capable of specifically amplifying the human ITM2A gene sequence. Preferably, the nucleotide sequences of the primer pairs are shown as SEQ ID NO.1 and SEQ ID NO. 2. Preferably, the kit is a fluorescent quantitative PCR kit, and the detection kit further comprises a fluorescent dye. Preferably, the kit further comprises a reference gene detection reagent, the reference gene being selected from GAPDH. Preferably, the kit further comprises reagents for extracting total RNA of the sample, reverse transcription reagents and/or PCR reaction buffers. Preferably, the sample is cervical tissue or paraffin embedded tissue of a cervical cancer patient. The invention also provides a primer pair for prognosis evaluation of cervical cancer, which can specifically amplify the sequence of human ITM2A gene, and the sequence is shown as SEQ ID NO.1 and SEQ ID NO. 2. The invention provides application of the kit or the primer pair in preparing a product for assessing prognosis of cervical cancer patients. By adopting the technical scheme, the kit has the beneficial effects that the kit comprises the primer pair capable of specifically amplifying human ITM2A gene sequences, and the expression level of ITM2A genes and encoding protei